{"id":135443,"date":"2026-07-26T08:38:10","date_gmt":"2026-07-26T08:38:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/135443\/"},"modified":"2026-07-26T08:38:10","modified_gmt":"2026-07-26T08:38:10","slug":"novo-nordisk-takes-lilly-to-court-over-glp-1-ad-claims-as-market-share-battle-intensifies","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/135443\/","title":{"rendered":"Novo Nordisk Takes Lilly to Court Over GLP-1 Ad Claims as Market Share Battle Intensifies"},"content":{"rendered":"<p>Novo Nordisk has escalated its legal confrontation with Eli Lilly, filing for a preliminary injunction in a New Jersey federal court on July 24 to halt what it calls misleading advertising for Lilly\u2019s Zepbound and Mounjaro. The move marks a sharp shift in strategy for the Danish drugmaker, which now aims to use the courts to counter a rival that has seized a commanding lead in the obesity market.<\/p>\n<p>At the heart of the dispute is a comparison Lilly has been running in its promotional materials, based on the SURMOUNT-5 head-to-head study. Novo Nordisk argues that the ads pit high doses of Lilly\u2019s drugs against outdated or lower doses of Wegovy, deliberately omitting the 7.2-milligram version that won FDA approval in March. The company claims this creates a false impression of Wegovy\u2019s efficacy. Lilly has pushed back, insisting its communications are truthful and transparent.<\/p>\n<p>The legal timeline is tight. A hearing on the injunction request is scheduled for August 17, just days after Novo Nordisk releases its second-quarter earnings on August 5. Analysts will be watching both events closely for clues on how the competitive dynamics are shifting.<\/p>\n<p>The Market Reality Behind the Courtroom Drama<\/p>\n<p>The numbers tell a stark story. Novo Nordisk now holds 42 percent of the obesity market, while Lilly commands 59.5 percent. That gap has widened as Lilly\u2019s portfolio has expanded rapidly \u2014 most notably with Foundayo, an oral pill that the FDA approved in a record 50 days, intensifying what has become a full-blown \u201cpill war\u201d over patient convenience.<\/p>\n<p style=\"margin: 2em 0; color: #374151; font-size: inherit; line-height: 1.6; font-style: italic;\"><a href=\"https:\/\/www.stockstoday.com\/lp\/analysis\/?trk=ST_Asset_Analysis_Middle_RSS-Feed&amp;isin=DK0062498333&amp;aktienname=Novo+Nordisk&amp;adref=Blog_Ad-Hoc-News%3AEx-Article-ID_200395%3AISIN_DK0062498333%3AAsset_Novo+Nordisk%3ASource_Ad-Hoc-News&amp;source=RSS-Ad-Hoc-News&amp;Language=English\" rel=\"noopener nofollow\" style=\"color: #337ab7 !important; font-weight: bold; text-decoration: underline;\" target=\"_blank\">Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n<p>Novo Nordisk does have a counterpunch of its own. The oral version of Wegovy has already generated more than 3 million prescriptions in the U.S., accounting for roughly 30 percent of all Wegovy scripts. That shift toward oral formulations is driving meaningful growth, and the newly approved higher dose gives doctors a clinical argument to counter Lilly\u2019s weight-loss claims.<\/p>\n<p>Institutional investors are taking note. Renaissance Technologies boosted its Novo Nordisk position by 6.7 percent in the first quarter, while Arrowstreet Capital initiated a new stake.<\/p>\n<p>Stock Price Caught Between Recovery and Resistance<\/p>\n<p>The shares closed the week at \u20ac42.85 on Friday, up 1.19 percent on the day. That leaves the stock 41.65 percent above its 52-week low from March, suggesting a solid floor has formed since the spring trough. But the recovery remains incomplete: the stock is still down 2.67 percent year-to-date and 29.70 percent below its July 2025 peak of \u20ac60.95.<\/p>\n<p style=\"margin: 2em 0; color: #374151; font-size: inherit; line-height: 1.6; font-style: italic;\"><a href=\"https:\/\/www.stockstoday.com\/lp\/analysis\/?trk=ST_Asset_Analysis_Middle2_RSS-Feed&amp;isin=DK0062498333&amp;aktienname=Novo+Nordisk&amp;adref=Blog_Ad-Hoc-News%3AEx-Article-ID_200395%3AISIN_DK0062498333%3AAsset_Novo+Nordisk%3ASource_Ad-Hoc-News&amp;source=RSS-Ad-Hoc-News&amp;Language=English\" rel=\"noopener nofollow\" style=\"color: #337ab7 !important; font-weight: bold; text-decoration: underline;\" target=\"_blank\">Novo Nordisk at a turning point? This analysis reveals what investors need to know now.<\/a><\/p>\n<p>Technical levels offer some guideposts. The shares are trading above their 200-day moving average of \u20ac40.38, a positive signal for the recovery trend. If the injunction is granted after the August 17 hearing, analysts see a realistic chance for the stock to stabilize above \u20ac43. A ruling in Lilly\u2019s favor, or signs that Foundayo is eroding Wegovy\u2019s prescription growth, could send the stock back toward its 50-day average of \u20ac40.36.<\/p>\n<p>The annualized 30-day volatility of 26.83 percent underscores how much uncertainty is priced in. Between the court date, the earnings release, and the relentless competitive pressure, Novo Nordisk\u2019s next few weeks will test whether its legal gambit can buy the time needed to close the gap with Lilly.<\/p>\n<p align=\"right\" style=\"font-size:10px;margin:0;\">Ad<\/p>\n<p style=\"margin-bottom: 1em;\">Novo Nordisk Stock: New Analysis &#8211; 26 July<\/p>\n<p style=\"margin-bottom: 1em;\">Fresh Novo Nordisk information released. What&#8217;s the impact for investors? Our latest independent report examines recent figures and market trends.<\/p>\n<p style=\"margin-bottom: 1em;\"><a href=\"https:\/\/www.stockstoday.com\/lp\/analysis\/?trk=ST_Asset_Analysis_Bottom_RSS-Feed&amp;isin=DK0062498333&amp;aktienname=Novo+Nordisk&amp;adref=Blog_Ad-Hoc-News%3AEx-Article-ID_200395%3AISIN_DK0062498333%3AAsset_Novo+Nordisk%3ASource_Ad-Hoc-News&amp;source=RSS-Ad-Hoc-News&amp;Language=English\" rel=\"noopener nofollow\" style=\"color: #337ab7 !important; font-weight: bold; text-decoration: underline;\" target=\"_blank\">Read our updated Novo Nordisk analysis&#8230;<\/a><\/p>\n<p style=\"margin-top:20px;margin-bottom:20px;\">&#13;<br \/>\n\t\t\t\t\t\tDisclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.&#13;\n\t\t\t\t\t<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk has escalated its legal confrontation with Eli Lilly, filing for a preliminary injunction in a New&hellip;\n","protected":false},"author":2,"featured_media":135444,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[6002,2261,3335,20640,4135,5691,3845,272,9278,1130,5692],"class_list":["post-135443","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-claims","tag-court","tag-glp-1","tag-lilly","tag-market","tag-nordisk","tag-novo","tag-novo-nordisk","tag-over","tag-share","tag-takes"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116985377976258045","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/135443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=135443"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/135443\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/135444"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=135443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=135443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=135443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}